ClearPoint Neuro reports record FY2024 revenue $31.4M, 31% growth; guides FY2025 $36-41M

ClearPoint Neuro, Inc.

2024-FY EPS reported -$0.70 revenue$31,390,000

FY 2024 revenue $31.4M (+31% YoY); Q4 revenue $7.8M (+14% YoY).
Gross margin improved to 61% from 57%; operating expenses rose 8% to $38.9M.
Repaid $10M convertible note; cash $20.1M; operational cash burn down 35% to $9.0M.
2025 revenue guidance $36-41M, implying 15-31% growth.
Biologics/drug delivery revenue up 76% to $18.6M; added 25 new centers in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.